Gilead Sciences
(NQ:
GILD
)
79.17
+0.45 (+0.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Gilead Sciences (GILD) Q2 2021 Earnings Call Transcript
July 30, 2021
GILD earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
July 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Gilead Sciences Exceeds Expectations As Remdesivir Success Cushions Slump In HIV Franchise
July 30, 2021
Gilead Sciences Inc (NASDAQ: GILD) reported Q2 sales of $6.2 billion +21% Y/Y, beating the consensus estimate of $6.07 billion, helped by solid demand for COVID-19...
Via
Benzinga
Amazon Earnings Could Take the Market Down with it
July 29, 2021
While we've seen sell-offs occur on recent positive earnings surprises, few have been dramatic and none has been as consequential as AMZN could be tomorrow.
Via
Talk Markets
Recap: Gilead Sciences Q2 Earnings
July 29, 2021
Shares of Gilead Sciences (NASDAQ:GILD) decreased 0.8% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 68.47% year...
Via
Benzinga
Gilead Earnings Top Views; Biotech Giant Narrows Guidance
July 29, 2021
Gilead earnings modestly beat Q2 views with the biotech giant narrowing its full-year EPS target range. Gilead dipped late.
Via
Investor's Business Daily
Eli Lilly-Incyte's Rheumatoid Arthritis Drug Gets OK From FDA For Solo Use In Hospitalized COVID-19 Patients
July 29, 2021
The FDA extended the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) rheumatoid...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
July 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Prioritizing the Needs of the Black LGBTQ+ Community in an Innovative HIV Trial
July 27, 2021
Prioritizing the Needs of the Black LGBTQ+ Community in an Innovative HIV Trial
Via
News Direct
A Look Into Gilead Sciences Price Over Earnings
July 27, 2021
Looking into the current session, Gilead Sciences Inc. (NASDAQ:GILD) shares are trading at $68.78, after a 0.1% increase. Moreover, over the past month, the stock...
Via
Benzinga
Gilead Ordered To Pay Attorney Fees In Shareholder Lawsuit
July 26, 2021
Gilead Sciences Inc. (NYSE: GILD) was ordered to pay about $1.8 million late last week in attorney’s fees and legal expenses to shareholders who sued the company after...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Understanding Gilead Sciences's Unusual Options Activity
July 26, 2021
Shares of Gilead Sciences (NASDAQ:GILD) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $68.81. Sentiment: BULLISH...
Via
Benzinga
Healthcare ETFs in Focus as Q2 Earnings Unfold
July 22, 2021
Let’s dig deeper into the earnings picture of the companies which will drive the performance of healthcare funds in the coming days.
Via
Talk Markets
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
Arcus Surges As Executive Transfer Could Signal Deeper Gilead Partnership
July 20, 2021
An Arcus executive jumped ship for a role at Gilead, but RCUS stock popped Tuesday on expectations for a closer relationship.
Via
Investor's Business Daily
Understanding Gilead Sciences's Unusual Options Activity
July 20, 2021
Shares of Gilead Sciences (NASDAQ:GILD) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved up to $69.14. Sentiment: BEARISH...
Via
Benzinga
Top-Rated Biotech Stock BioNTech Tacks On New Cancer Business With Kite Platform Buy
July 19, 2021
BioNTech stock rose Monday after the company said it was acquiring a manufacturing site and a platform from a Gilead Sciences subsidiary.
Via
Investor's Business Daily
Four-Year Biktarvy Data Show High Efficacy, Durable Viral Suppression In Untreated HIV Patients
July 19, 2021
Gilead Sciences Inc (NASDAQ: GILD) announced long-term Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) data showing high...
Via
Benzinga
Gilead's Lenacapavir Shows High Rates Of Virologic Suppression In Heavily Treated HIV Patients
July 19, 2021
Gilead Sciences Inc (NASDAQ: GILD) announced new Phase 3 data from the ongoing CAPELLA trial evaluating lenacapavir, its investigational, long-acting HIV-1 capsid...
Via
Benzinga
Analyzing Gilead Sciences's Unusual Options Activity
July 16, 2021
Gilead Sciences (NASDAQ:GILD) shares experienced unusual options activity on Friday. The stock price moved up to $68.72 following the option alert. Sentiment: BULLISH Option...
Via
Benzinga
Moderna Is Now More Valued Than Gilead, GlaxoSmithKline: How Long Did COVID-19 Vaccine Maker Take To Hit $100B?
July 15, 2021
Moderna Inc (NASDAQ: MRNA) stock is on a roll, with its vaccine-induced momentum spilling over into 2021. The Massachusetts-based company, which had a modest beginning...
Via
Benzinga
Exposures
COVID-19
Investing $72,036 Into These 3 Stocks Can Generate $300 in Monthly Income for Your Portfolio
July 14, 2021
And there's a good chance you could be earning even more than that.
Via
The Motley Fool
2 Biotech Stocks That are Dirt Cheap Right Now
July 13, 2021
Biotech companies responded to the COVID-19 pandemic in a remarkable way, with vaccinations, treatments, diagnostics, and variant monitoring.
Via
Talk Markets
Exposures
COVID-19
Gilead's Remdesivir Fails To Show Antiviral Effects Against COVID-19 In Small WHO Study
July 13, 2021
According to a study published in the Annals of Internal Medicine, neither Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) nor hydroxychloroquine (HCQ)...
Via
Benzinga
Exposures
COVID-19
Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy?
July 10, 2021
The battle for market share could come down to which drug has the lesser side effects.
Via
The Motley Fool
Understanding Gilead Sciences's Unusual Options Activity
July 08, 2021
Gilead Sciences (NASDAQ:GILD) shares experienced unusual options activity on Thursday. The stock price moved down to $67.64 following the option alert. Sentiment: BULLISH Option...
Via
Benzinga
Analyzing Gilead Sciences's Unusual Options Activity
July 02, 2021
Shares of Gilead Sciences (NASDAQ:GILD) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved up to $69.27. Sentiment: BEARISH...
Via
Benzinga
Donald Rumsfeld, Two-Time Defense Secretary, Dies At 88
June 30, 2021
Donald Rumsfeld, who served as Secretary of Defense when President George W. Bush sent U.S. military forces into Afghanistan in pursuit of al-Qaeda and into Iraq to topple the...
Via
Benzinga
Gilead, Foresite Take Pardes Biosciences Public In $250M SPAC Deal
June 29, 2021
Pardes Biosciences Inc, an early-stage biopharmaceutical company, and FS Development Corp. II (NASDAQ: FSII), a Foresite Capital sponsored SPAC, entered into a...
Via
Benzinga
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
June 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...
Via
Benzinga
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.